Theranostics infrastructure
Pioneering theranostics advancements
GMP-standard radiopharmaceutical and theranostic infrastructure for hospitals across ASEAN and South Asia.
Whole-chain capability
- Facility design
- Cyclotron
- Radiopharmacy
- Synthesis
- Quality control
- Molecular imaging
Theranostic care
See what you treat. Treat what you see.
A theranostic agent binds to a targeted biomarker, letting clinicians identify disease at the molecular level — then a therapeutic dose of the same or a related agent destroys the diseased cells, sparing the healthy tissue that conventional chemotherapy cannot avoid.
- Diagnose. A targeting molecule carries a diagnostic isotope to the tumour.
- Image. PET imaging confirms the target is present and maps it.
- Treat. The same molecule delivers a therapeutic isotope to that target.
Solutions across the whole value chain
From facility design and cyclotron installation through synthesis, dispensing, quality control and imaging — specified, delivered and supported as one programme.
Facility Design ServiceGMP facility design, build, and equip — from site feasibility to commissioning.
Cyclotron SolutionsThe particle accelerator behind every PET scan and targeted radiotherapy dose.
Synthesis SolutionsNEPTIS® automated synthesizers for [18F], [68Ga], and beyond.
Radiopharmacy SolutionsFrom cyclotron to release — GMP radiopharmacy production as one integrated workflow.
Quality Control SolutionsA complete radiopharmaceutical QC lab in under 2m².
Radiation Protection EquipmentComecer shielded hot cells — protecting operators without slowing production.
Molecular ImagingPET-CT and PET-MRI systems for high-resolution, low-dose diagnostic imaging.
Theranostics SolutionsTherapeutics + Diagnostics = Theranostics — see what you treat, treat what you see.Equipment we deliver
Browse the full catalogThe specialists behind the work
Meet the teamJ. Paul Shea, PhD
PhD Medicinal Chemist
Radiochemistry & PET Tracer Development — Luminare Molecular
John P. Doumitt, PE
BS Professional Engineer (Industrial Engineering), MS Management (Purdue University)
GMP Facility Design & Construction Management
Farhad Karimi, PhD
PhD Organic Radiochemist, Uppsala University (IMANET PET Center)
Vice President, Radiochemistry & Regulatory Affairs — Luminare Molecular
Nicola "Nick" Ceccomancini
GMP Radiopharmacy Consulting
Bangladesh expansion
Building Bangladesh's national theranostics capability
Bangladeshi patients spend an estimated US$5 billion a year on cancer care abroad. MED I is positioned to help close that gap with a national theranostics and isotope-production hub.
Med I Academy
Browse all articlesPlanning a radiopharmacy, cyclotron or theranostics programme?
Tell us what you're building. We'll come back with scope, equipment options and a realistic path to a GMP-compliant facility.